...
首页> 外文期刊>Pediatric transplantation. >Successful hematopoietic stem cell transplantation from an HLA‐mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases
【24h】

Successful hematopoietic stem cell transplantation from an HLA‐mismatched parent for engraftment failure after unrelated cord blood transplantation in patients with juvenile myelomonocytic leukemia: Report of two cases

机译:少年骨髓细胞白血病患者的无关脐带血血液移植后,从HLA - 错配母体中成功的造血干细胞移植术后两病例报告

获取原文
获取原文并翻译 | 示例

摘要

Abstract JMML is an aggressive hematopoietic malignancy of early childhood, and allogeneic HSCT is the only curative treatment for this disease. Umbilical cord blood is one of donor sources for HSCT in JMML patients who do not have an HLA‐compatible relative, but engraftment failure remains a major problem. Here, we report two cases of JMML who were successfully rescued by HSCT from an HLA‐mismatched parent after development of primary engraftment failure following unrelated CBT. Both patients had severe splenomegaly and underwent unrelated CBT from an HLA‐mismatched donor. Immediately after diagnosis of engraftment failure, both patients underwent HSCT from their parent. For the second HSCT, we used RIC regimens consisting of FLU, CY, and a low dose of rabbit ATG with or without TBI and additionally administered ETP considering their persistent severe splenomegaly. Both patients achieved engraftment without severe treatment‐related adverse effects. After engraftment of second HSCT, their splenomegaly was rapidly regressed, and both patients showed no sign of relapse for over 4?years. These observations demonstrate that HSCT from an HLA‐mismatched parent could be a feasible salvage treatment for primary engraftment failure in JMML patients.
机译:摘要JMML是一种侵略性的孕肥恶性肿瘤,而同种异体的HSCT是这种疾病的唯一治疗方法。脐脐血是HSCT中的捐赠源之一,其JMML患者没有HLA兼容的亲属,但植入失败仍然是一个主要问题。在这里,我们报告了两种JMML的案例,他在未密封的CBT开发初级植入失败后由HLA-错配的父母成功救出。两种患者都有严重的脾肿大和来自HLA错配的供体的无关的CBT。诊断植入失败后立即,两名患者都从他们的父母接受了HSCT。对于第二个HSCT,我们使用的RIC方案由流感,CY和低剂量的兔ATG组成,并且在考虑其持续的严重脾肿大的情况下另外给予ETP。两名患者均达到植入而没有严重治疗相关的不良反应。在第二次HSCT植入后,它们的脾肿大迅速消退,两名患者没有超过4年的复发迹象。这些观察结果表明,来自HLA失配的父母的HSCT可以是JMML患者中初级植入失败的可行的销售处理。

著录项

  • 来源
    《Pediatric transplantation. 》 |2019年第3期| 共5页
  • 作者单位

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Hematology and OncologyNagano Children's HospitalNagano Japan;

    Department of PediatricsNagoya University Graduate School of MedicineNagoya Japan;

    Department of PediatricsNagoya University Graduate School of MedicineNagoya Japan;

    Department of PediatricsNagoya University Graduate School of MedicineNagoya Japan;

    Department of Pediatrics Shinonoi General HospitalMinami Nagano CenterNagano Japan;

    Department of PediatricsNagoya University Graduate School of MedicineNagoya Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

    Department of Pediatrics Faculty of MedicineUniversity of YamanashiYamanashi Japan;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 儿科学 ;
  • 关键词

    CBT; engraftment failure; GVHD; HLA‐mismatched parent; JMML; RIC;

    机译:CBT;植入失败;GVHD;HLA - 不匹配的父母;JMML;RIC;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号